- Home
- NIO vs BBIO Comparison
NIO vs BBIO Comparison
Compare NIO & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NIO | BBIO |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | United States |
| Employees | 45635 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8B | 15.3B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NIO | BBIO |
|---|---|---|
| Price | $6.29 | $73.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 24 |
| Target Price | $6.73 | ★ $85.43 |
| AVG Volume (30 Days) | ★ 38.4M | 1.7M |
| Earning Date | 03-10-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $52.19 | $88.16 |
| Revenue Next Year | $20.45 | $74.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $3.02 | $28.33 |
| 52 Week High | $8.02 | $84.94 |
Technical Indicators
Market Signals| Indicator | NIO | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 64.25 | 55.22 |
| Support Level | $6.28 | $69.62 |
| Resistance Level | $6.83 | $78.20 |
| Average True Range (ATR) | 0.27 | 2.64 |
| MACD | 0.03 | 0.59 |
| Stochastic Oscillator | 93.46 | 68.85 |
Price Performance
Historical ComparisonAbout NIO NIO Inc. American depositary shares each representing one ordinary share
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 326,000 EVs in 2025, accounting for about 2% of the China passenger new energy vehicle market.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.